Key facts
- This page summarizes Benny Sorensen's Form 4 filing for Codiak BioSciences, Inc..
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Sep 2021, 16:05.
Benny Sorensen - 08 Jun 2021 Form 4 Insider Report for Codiak BioSciences, Inc.
- Reporting relationship
- Former SVP, Clinical Development
- Issuer ticker
- N/A
- Reported as of
- 08 Jun 2021
- Net transaction value
- -$190,942
- SEC form
- 4
- Accepted by SEC
- 28 Sep 2021, 16:05:40 UTC
- Next SEC filing
- 30 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yalonda Howze, by Power of Attorney for Benny Sorensen
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Benny Sorensen filed Form 4 for Codiak BioSciences, Inc. on 28 Sep 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$190,942.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CDAKQ
transaction
Common Stock
Options Exercise
- Transaction value
- $28,074
- Shares
- +8,533
- Change %
- Price
- $3.29*
- Shares after
- 8,533
- Date
- 08 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
CDAKQ
transaction
Common Stock
Sale
- Transaction value
- $176,276
- Shares
- -6,893
- Change %
- -81%
- Price
- $25.57*
- Shares after
- 1,640
- Date
- 08 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3
CDAKQ
transaction
Common Stock
Sale
- Transaction value
- $42,740
- Shares
- -1,640
- Change %
- -100%
- Price
- $26.06*
- Shares after
- 0
- Date
- 08 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDAKQ
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- +8,533
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 87,411
- Date
- 08 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,533
- Exercise price
- $3.29
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a previously adopted Rule 10b5-1 trading plan.
Footnote F3
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $25.00 to $25.99 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Footnote F4
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $26.00 to $26.13 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Footnote F5
The shares underlying this option are fully vested.
SEC remarks
Former SVP, Clinical Development